Somewhat Positive Press Coverage Somewhat Unlikely to Affect Natus Medical (BABY) Stock Price

News articles about Natus Medical (NASDAQ:BABY) have trended somewhat positive on Thursday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Natus Medical earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 46.6129557513552 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

BABY has been the topic of several research analyst reports. Zacks Investment Research raised Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a research report on Tuesday, October 24th. BidaskClub downgraded Natus Medical from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 24th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $46.50.

Shares of Natus Medical (BABY) opened at $38.25 on Thursday. The stock has a market capitalization of $1,208.78, a PE ratio of 25.03 and a beta of 0.84. Natus Medical has a 1 year low of $31.65 and a 1 year high of $43.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.02. The company had revenue of $122.60 million for the quarter, compared to the consensus estimate of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The firm’s revenue was up 34.9% compared to the same quarter last year. During the same period last year, the business posted $0.39 earnings per share. sell-side analysts predict that Natus Medical will post 1.74 EPS for the current year.

In related news, Director William M. Moore sold 5,000 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $41.01, for a total value of $205,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert A. Gunst sold 4,400 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $35.17, for a total transaction of $154,748.00. Following the completion of the sale, the director now owns 50,850 shares of the company’s stock, valued at approximately $1,788,394.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,042 shares of company stock valued at $902,266. 5.50% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Natus Medical (BABY) Stock Price” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.com-unik.info/2017/12/07/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-natus-medical-baby-stock-price.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

What are top analysts saying about Natus Medical Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Natus Medical Incorporated and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit